# Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

> **NCT05518032** · PHASE2 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Metastatic Microsatellite Stable Colorectal Carcinoma
- Recurrent Colorectal Carcinoma
- Stage III Colorectal Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Unresectable Colorectal Carcinoma

## Interventions

- **PROCEDURE:** Biopsy
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Therapeutic Autologous Dendritic Cells

## Key facts

- **NCT ID:** NCT05518032
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-10-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** prioritization of studies
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518032, "Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05518032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*